JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2005; 46:2311-2321, doi:10.1016/j.jacc.2005.08.033
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldman, A. M.
Right arrow Articles by Gunderman, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldman, A. M.
Right arrow Articles by Gunderman, M. R.

CLINICAL RESEARCH: COST EFFECTIVENESS AND REGULATORY CONSIDERATIONS

Cost Effectiveness of Cardiac Resynchronization Therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial

Arthur M. Feldman, MD, PhD, FACC*,*, Gregory de Lissovoy, PhD{dagger},{ddagger}, Michael R. Bristow, MD, PhD, FACC§, Leslie A. Saxon, MD, FACC||, Teresa De Marco, MD, FACC, David A. Kass, MD, FACC{ddagger}, John Boehmer, MD, FACC#,**, Steven Singh, MD, FACC{dagger}{dagger},{ddagger}{ddagger}, David J. Whellan, MD*, Peter Carson, MD, FACC{dagger}{dagger},{ddagger}{ddagger}, Audra Boscoe, MPH{dagger}, Timothy M. Baker, BS{dagger} and Matthew R. Gunderman, MBA§§

* Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania
{dagger} MEDTAP Institute at UBC, Bethesda, Maryland
{ddagger} Department of Health Policy Management, Johns Hopkins School of Public Health, Baltimore, Maryland
§ Division of Cardiology, University of Colorado, Denver, Colorado
|| Division of Cardiology, University of Southern California, Los Angeles, California
Division of Cardiology, University of California, San Francisco, California
# Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
** Division of Cardiology, Hershey Medical Center, Hershey, Pennsylvania
{dagger}{dagger} Department of Medicine and Pharmacology at Georgetown University School of Medicine, Washington, DC
{ddagger}{ddagger} Veterans Affairs Medical Center, Washington, DC
§§ Guidant Corporation, St. Paul, Minnesota

Manuscript received February 25, 2005; revised manuscript received July 7, 2005, accepted August 9, 2005.

* Reprint requests and correspondence: Dr. Arthur M. Feldman, Department of Medicine, Jefferson Medical College, 1025 Walnut Street, Philadelphia, Pennsylvania 19107 (Email: arthur.feldman{at}jefferson.edu).

A preliminary report of this work was presented at the 54th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, 2005.

OBJECTIVES: The analysis goal was to estimate incremental cost-effectiveness ratios (ICERs) for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial patients who received cardiac resynchronization therapy (CRT) via pacemaker (CRT-P) or pacemaker-defibrillator (CRT-D) in combination with optimal pharmacological therapy (OPT) relative to patients with OPT alone.

BACKGROUND: In the COMPANION trial, CRT-P and CRT-D reduced the combined risk of all-cause mortality or first hospitalization among patients with advanced heart failure and intraventricular conduction delays, but the cost effectiveness of the therapy remains unknown.

METHODS: In this analysis, intent-to-treat trial data were modeled to estimate the cost effectiveness of CRT-D and CRT-P relative to OPT over a base-case seven-year treatment episode. Exponential survival curves were derived from trial data and adjusted by quality-of-life trial results to yield quality-adjusted life-years (QALYs). For the first two years, follow-up hospitalizations were based on trial data. The model assumed equalized hospitalization rates beyond two years. Initial implantation and follow-up hospitalization costs were estimated using Medicare data.

RESULTS: Over two years, follow-up hospitalization costs were reduced by 29% for CRT-D and 37% for CRT-P. Extending the cost-effectiveness analysis to a seven-year base-case time period, the ICER for CRT-P was $19,600 per QALY and the ICER for CRT-D was $43,000 per QALY relative to OPT.

CONCLUSIONS: For the COMPANION trial patients, the use of CRT-P and CRT-D was associated with a cost-effectiveness ratio below generally accepted benchmarks for therapeutic interventions of $50,000 per QALY to $100,000 per QALY. This suggests that the clinical benefits of CRT-P and CRT-D can be achieved at a reasonable cost.

Abbreviations and Acronyms
  COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure trial
  CRT = cardiac resynchronization therapy
  CRT-D = cardiac resynchronization therapy with pacemaker-defibrillator
  CRT-P = cardiac resynchronization therapy with pacemaker
  DRG = diagnostic-related group
  ICER = incremental cost-effectiveness ratio
  LV = left ventricular
  MLHFQ = Minnesota Living With Heart Failure Questionnaire
  NYHA = New York Heart Association
  OPT = optimal pharmacological therapy
  QALY = quality-adjusted life-year




This article has been cited by other articles:


Home page
EuropaceHome page
L. Ding, W. Hua, H. Niu, K. Chen, and S. Zhang
Primary prevention of sudden cardiac death using implantable cardioverter defibrillators
Europace, September 1, 2008; 10(9): 1034 - 1041.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
S. K H Lam and A. Owen
Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials
BMJ, November 3, 2007; 335(7626): 925 - 925.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Europace, October 1, 2007; 9(10): 959 - 998.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Eur. Heart J., September 2, 2007; 28(18): 2256 - 2295.
[Full Text] [PDF]


Home page
JAMAHome page
F. A. McAlister, J. Ezekowitz, N. Hooton, B. Vandermeer, C. Spooner, D. M. Dryden, R. L. Page, M. A. Hlatky, and B. H. Rowe
Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction: A Systematic Review
JAMA, June 13, 2007; 297(22): 2502 - 2514.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. A. Hlatky and D. B. Mark
The high cost of implantable defibrillators
Eur. Heart J., February 2, 2007; 28(4): 388 - 391.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Yao, N. Freemantle, M. J. Calvert, S. Bryan, J.-C. Daubert, and J. G.F. Cleland
The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator
Eur. Heart J., January 1, 2007; 28(1): 42 - 51.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Kramer
The Expanding Prognostic Role of Late Gadolinium Enhanced Cardiac Magnetic Resonance
J. Am. Coll. Cardiol., November 21, 2006; 48(10): 1986 - 1987.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. M. Krumholz and F. A. Masoudi
The Year in Epidemiology, Health Services Research, and Outcomes Research
J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1886 - 1895.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Ward, S. Guo, and J. J. Caro
Cost-Effectiveness of Cardiac Resynchronization Therapy
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1283 - 1283.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P. Kearney, G. Stokoe, G. Breithardt, C. Longson, J. Marco, J. Morgan, S. Priori, A. Ruether, R. Taylor, M. Hertog, et al.
Improving patient access to novel medical technologies in Europe
Eur. Heart J., April 1, 2006; 27(7): 882 - 885.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
O.-A. Breithardt and G. Breithardt
Quest for the Best Candidate: How Much Imaging Do We Need Before Prescribing Cardiac Resynchronization Therapy?
Circulation, February 21, 2006; 113(7): 926 - 928.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. A. Hlatky
Cost Effectiveness of Cardiac Resynchronization Therapy
J. Am. Coll. Cardiol., December 20, 2005; 46(12): 2322 - 2324.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.